RCAN3
Calcipressin-3
Protein Summary
Inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A. Could play a role during central nervous system development (By similarity).
- ENST00000374393
- ENSP00000363514
- ENSG00000117602
- ENST00000374395
- ENSP00000363516
- ENST00000412742
- ENSP00000391912
- ENST00000425530
- ENSP00000409540
- ENST00000436717
- ENSP00000414447
- ENST00000538532
- ENSP00000445401
- ENST00000610732
- ENSP00000479300
- ENST00000616511
- ENSP00000478174
- ENST00000618490
- ENSP00000484519
- ENST00000630217
- ENSP00000486836
- DSCR1L2
- RCN3
- MCIP3
- hRCN3
- DSCR1L2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
cell type or tissue | 0.86 | ||
transcription factor perturbation | 0.84 | ||
small molecule perturbation | 0.65 | ||
histone modification site profile | 0.64 | ||
disease perturbation | 0.62 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 10.55 (req: < 5)
Gene RIFs: 10 (req: <= 3)
Antibodies: 238 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 10.55 (req: >= 5)
Gene RIFs: 10 (req: > 3)
Antibodies: 238 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0